Edition:
India

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

8.10USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
111,691
52-wk High
$14.00
52-wk Low
$6.25

Select another date:

Tue, Dec 12 2017

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

BRIEF-HitGen and Aduro Enter Research Collaboration

* Entered into a multi-target multi-year collaboration with Aduro Biotech Inc

BRIEF-Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders‍​

* Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders‍​ - sec filing Source text - http://bit.ly/2v0rE5d Further company coverage:

BRIEF-Aduro Biotech files for mixed shelf of upto $300 mln

* Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing Source text - http://bit.ly/2w7SKYi Further company coverage:

BRIEF-Aduro Biotech Q2 loss per share $0.27

* Aduro Biotech reports second quarter 2017 financial results

BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck

* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​

Select another date: